Close

Mizuho Securities Raises Price Target on Ironwood Pharma (IRWD) Following 3Q Beat

Go back to Mizuho Securities Raises Price Target on Ironwood Pharma (IRWD) Following 3Q Beat

Ironwood Pharmaceuticals Provides Third Quarter 2016 Investor Update

November 3, 2016 8:01 AM EDT

Ironwood revenue increased 67% to $66 million in 3Q 2016 over 3Q 2015

Linzess® (linaclotide) U.S. net sales increased 40% to $164 million in 3Q 2016 over 3Q 2015; net profit for the brand increased 128% to $82 million in same period

Zurampic® (lesinurad) launched in October 2016; Ironwood salesforce now bringing three products to primary care physicians

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc.... More